Medscape is available in 5 Language Editions – Choose your Edition here.


Childhood Disintegrative Disorder

  • Author: Bettina E Bernstein, DO; Chief Editor: Caroly Pataki, MD  more...
Updated: Jun 28, 2016

Practice Essentials

Childhood disintegrative (or disintegration) disorder, also known as Heller syndrome, is characterized by a loss of previously acquired language and social skills and results in a persistent delay in these areas. For example, a child previously able to speak in 2- or 3-word phrases gradually or abruptly loses the ability to communicate using words or can use only fragments.

Social and emotional development also regress, resulting in an impaired ability to relate with others. For example, a child who was previously able to accept reassurance from his or her parent (eg, a hug) loses the ability to be consoled and may even withdraw from human (tactile) contact.

Childhood disintegrative disorder occurs in about 2 per 100,000 children and thus is much rarer than either autistic disorder, which affects 20 per 10,000 children, or pervasive developmental disorder, not otherwise specified (PDD-NOS), which occurs in 30 per 10,000 children.[1] Childhood disintegrative disorder generally manifests by the fourth year of life, after a period of at least 2 years of normal development.

Overall, the social, communicative, and behavioral features of childhood disintegrative disorder resemble those of autistic disorder. Affected children have distinct qualitative impairments in social interaction and communication. In addition, restricted, repetitive, or stereotyped patterns of behavior, interests, and activities occur. Previously acquired motor skills are lost (eg, a child who was toilet-trained begins to soil during the day and night, or a child who was able to pedal a tricycle or draw shapes can no longer do so).



Childhood disintegrative (or disintegration) disorder may be associated with lysosomal storage disorders such as late-onset Tay-Sachs disease(LOTS). A recent case report of a patient with symptoms of childhood disintegrative disorder at age 4 years determined that the patient had a sialylation deficiency and an increase of asialo-core fucosylated bisected N-glycans, aberrant N-glycan structures of CSF even though there were no changes of total plasma N-glycan strucutres of CSF proteins.[2]

Additional symptoms of childhood disintegrative disorder may include the onset of difficulty in the transition to waking from sleep. Social interactions become compromised (as manifested by aggressiveness, tantrums, or withdrawal from peers), as does motor function, resulting in poor coordination and possible awkwardness of gait.[3]

Family home movies can be very helpful in early identification of autistic spectrum disorders (ASDs), including childhood disintegrative disorder.[4]

Illustrative case

A 3-year-old boy is referred for evaluation because his behavior has recently gotten him “expelled” from daycare. He screams, throws tantrums, and no longer accepts hugs from his daycare teacher, with whom he was previously familiar. He has lately become destructive to his toys and does not use them to interact with his peers. His parents report that he was doing “okay” up until the past 3 months. They do not report that he had had any language delays.



It was long held, erroneously, that “refrigerator mothers” (a term coined on the basis of the presumed emotional frigidity of such mothers toward their children) caused ASDs in their children. This flawed theory has caused unnecessary psychological pain in countless families. However, current research has yet to reveal a clear-cut pathophysiology for childhood disintegrative disorder, and there remains considerable debate within the developmental disabilities field regarding the long-term outcomes of children with this condition.

Some researchers hypothesize that genetic predispositions combined with environmental stressors (eg, virus exposure or birth trauma) result in brain deposition of amyloid and disruption of synaptic transmissions, possibly involving interleukin-1 (IL-1) or beta-endorphins. Provision of enriched environmental experiences during critical periods of development may restore brain plasticity and thus mitigate genetic predispositions. However, earlier disruption of psychosocial development can result in even more severe developmental consequences.

Several researchers have theorized that altered or inappropriate immune responses, potentially involving abnormal B-cell activation and neuronal function, may play a role in the pathophysiology. In this regard, some studies have found that lithium and hyperbaric oxygen[5] reduce oxidative stress and may increase blood flow to the brain, lending some support to the idea that a possible endophenotype leads to oxidative stress and neuronal injury.[1, 6, 7, 8] A much smaller subset of children with ASD who show onset of symptoms or behavioral deterioration after viral or infectious insults may have this response due to a specific polysaccharide antibody deficiency (SPAD) that may respond to treatment with IV immunoglobulin.[9]

Autoantibodies to myelin basic protein (MBP) in children with childhood disintegrative disorder appear to differ from those in children with nonregressive forms of autism; however, this finding has not yet been shown to correlate with disease severity or prognosis.[6]

No gene has yet been isolated as the cause of childhood disintegrative disorder; however, a gene that codes for elongator protein complex 4 (ELP4) has been identified on human chromosome 11 and appears to be associated with centrotemporal spikes (CTS), the electroencephalographic (EEG) feature typical of rolandic epilepsy (RE).

ELP4 is one component of the elongator complex, a group of 6 genes that function in transcription and modification of transfer RNA (including regulating the actin cytoskeleton, cell motility, and migration) and that seem to play a critical role in influencing genes important to neuronal migration, axon growth, motility of growth cones, and related activities.[10]

ELP4 may also play a critical role in the transcription and modification of transfer RNA. Interference with necessary migration, synaptogenesis, and division in the central nervous system (CNS) before adolescence may result from disruption of transcriptional regulatory and translational modification roles and may render dendrites unable to make the proper neuronal connections.[11]

ASDs, including PDD, are generally associated with an increased incidence of seizures. Other idiopathic focal epilepsies occur during sleep. In addition, other epilepsy syndromes are associated with impaired frontal lobe and language function, potentially leading to continuous epileptiform discharges during sleep.[12]



No single causative factor for childhood disintegrative disorder has been identified. Research suggests that a combination of genetic susceptibility, including possibly abnormal autoimmunity, and prenatal (or environmental) stress may explain the pathophysiologic findings of higher-than-expected brain deposition of amyloid and disruption of synaptic transmission.

As the child experiences developmental departure from normality, the diminished preferential attention to the eyes of others has cascading detrimental effects, decreasing further socialization. The child’s attention focuses on aspects (eg, point sounds, lights, and lip motions), leading to further impairment of appropriate social interaction (mediated by eye contact and facial expression).[13]

Environmental risk factors for childhood disintegrative disorder include the following:

  • Viral exposure (and possibly bacterial infectious exposure for some vulnerable children; however, the more common pathway is usually intrauterine transmission) - Toxoplasmosis, other infections, rubella, cytomegalovirus infection, and herpes simplex (TORCH)
  • Birth trauma
  • Toxin exposure
  • Teratogenicity
  • Association of increased risk of ASD with in utero exposure to antiepileptic drugs: Meador and Loring in a recent review found up to an 8-fold increased risk of ASD associated with in utero exposure to valproate such that the American Association of Neurology has recommended avoidance of valproate during pregnancy whenever possible

Research directions include the possible association of ophthalmologic malformations with ASDs resulting from the teratogenicity of thalidomide and misoprostol[14]

Genetic factors include the following:

  • Possible susceptibility to chromosomal breakage or disruption
  • Family history of autism or Asperger disorder
  • Family history of RE, with or without CTS – RE commonly affects prepubescent children aged 3-12 years, occurring in about 1 per 500 children (60% of whom are boys); seizures in RE typically begin as groaning noises (in the larynx) that interfere with speech and then may present as sensorimotor activity; seizures in benign RE (BRE) occur at night and during sleep, possibly because sleep is associated with a lowered seizure threshold [15, 16]
  • CTS are also associated with attention deficit/hyperactivity disorder (ADHD), speech disorders, and developmental coordination disorder; in many cases, CTS due to RE are missed because the child’s history of falls can be mistakenly attributed to poor coordination [16]
  • A specific polysaccharide antibody deficiency (SPAD) [9]

Disorders associated with childhood disintegrative disorder include the following:

  • Autoimmune disorders [17]
  • Allergies (eg, food sensitivity reactions) and gastrointestinal (GI) disorders, which may show differences in GI bacterial composition in individuals with autism (Recent work on the microbiology of autism subjects’ stool specimens show that the presence of Desulfovibrio species and the impact of penicillins and cephalosporins, including clindamycin, can predispose to the overgrowth of Clostridium difficile. This may eventually lead to a role of probiotics for those individuals with prominent GI symptoms. [18, 19] ) and which may include asthma [20]
  • Insomnia [21]
  • Vitamin B-12 deficiency [22]
  • Hyperhomocysteinemia [22]
  • Anti – NMDA-receptor encephalitis [23, 24]


In the United States, childhood disintegrative disorder is very rare (affecting 2 per 100,000 children), much rarer than autistic disorder (which affects 20 per 10,000 children).[1] No current studies are large enough to determine the international frequency of childhood disintegrative disorder.

Childhood disintegrative disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), occurs only after a period of at least 2 years of normal development, when the child is younger than 10 years.[25, 1] Onset generally occurs in children aged 3-4 years and may be insidious or abrupt. The average age at diagnosis is 3.9 years, comparable to that of autistic disorder (average age, 3.1 years; range, 4.1-5.5 years in some studies).[1]

Childhood disintegrative disorder is slightly more common in males than in females.[1] No studies have shown childhood disintegrative disorder to be any more or less common in any particular race or culture.



The prognosis of childhood disintegrative disorder has been considered guarded; because the disorder is so rare, more data are needed.[3] Children with moderate-to-severe mental retardation or lack of communicative language have a worse prognosis than those with usual intelligence and communicative language.[3, 26] The disorder is lifelong, and the social, communicative, and behavioral difficulties tend to impair function throughout life.[3, 27]

No mortality or morbidity is directly attributable to childhood disintegrative disorder. Indirectly, a comorbid medical condition, such as a neurodegenerative disorder, may increase the risk of mortality and morbidity. The clinician should be alert to the possibility of Landau-Kleffner syndrome (LKS).[28, 29]

LKS is a rare condition of unknown etiology that is more common in boys. LKS generally presents with more severe language impairment and later than childhood disintegrative disorder; LKS has a mean age of onset of 5.5 years. Excluding this syndrome is important because it is generally associated with seizure disorder and may respond to treatment with anticonvulsants such as valproic acid or steroids.[28, 29]

The risk of seizures increases with age and peaks at adolescence. Concomitant administration of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and low-dose high-potency neuroleptics such as haloperidol tends to lower the seizure threshold (as does alcohol), which may increase the likelihood of seizures.[30]

Contributor Information and Disclosures

Bettina E Bernstein, DO Distinguished Fellow, American Academy of Child and Adolescent Psychiatry; Distinguished Fellow, American Psychiatric Association; Clinical Assistant Professor of Neurosciences and Psychiatry, Philadelphia College of Osteopathic Medicine; Clinical Affiliate Medical Staff, Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia; Consultant to theVillage, Private Practice; Consultant PMHCC/CBH at Family Court, Philadelphia

Bettina E Bernstein, DO is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, American Psychiatric Association

Disclosure: Nothing to disclose.

Chief Editor

Caroly Pataki, MD Health Sciences Clinical Professor of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, David Geffen School of Medicine

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, Physicians for Social Responsibility

Disclosure: Nothing to disclose.


Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

  1. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009 Jun. 65(6):591-8. [Medline].

  2. Barone R, Sturiale L, Fiumara A, Palmigiano A, Bua RO, Rizzo R, et al. CSF N-glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorder. Autism Res. 2016 Apr. 9 (4):423-8. [Medline].

  3. Volkmar FR, State M, Klin A. Autism and autism spectrum disorders: diagnostic issues for the coming decade. J Child Psychol Psychiatry. 2009 Jan. 50(1-2):108-15. [Medline].

  4. Palomo R, Thompson M, Colombi C, Cook I, Goldring S, Young GS, et al. A case study of childhood disintegrative disorder using systematic analysis of family home movies. J Autism Dev Disord. 2008 Nov. 38(10):1853-8. [Medline].

  5. Rossignol DA, Rossignol LW, Smith S, Schneider C, Logerquist S, Usman A, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009 Mar 13. 9:21. [Medline]. [Full Text].

  6. Libbey JE, Coon HH, Kirkman NJ, Sweeten TL, Miller JN, Stevenson EK, et al. Are there enhanced MBP autoantibodies in autism?. J Autism Dev Disord. 2008 Feb. 38(2):324-32. [Medline].

  7. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003 Apr. 160(4):636-45. [Medline].

  8. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008 Aug. 29(4):293-302. [Medline].

  9. Jyonouchi H, Geng L, Streck DL, Toruner GA. Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J Neuroinflammation. 2012 Jan 7. 9:4. [Medline]. [Full Text].

  10. Strug LJ, Clarke T, Chiang T, Chien M, Baskurt Z, Li W, et al. Centrotemporal sharp wave EEG trait in rolandic epilepsy maps to Elongator Protein Complex 4 (ELP4). Eur J Hum Genet. 2009 Sep. 17(9):1171-81. [Medline]. [Full Text].

  11. Ortega-Hernandez OD, Kivity S, Shoenfeld Y. Olfaction, psychiatric disorders and autoimmunity: is there a common genetic association?. Autoimmunity. 2009 Jan. 42(1):80-8. [Medline].

  12. Lillywhite LM, Saling MM, Harvey AS, Abbott DF, Archer JS, Vears DF, et al. Neuropsychological and functional MRI studies provide converging evidence of anterior language dysfunction in BECTS. Epilepsia. 2009 Oct. 50(10):2276-84. [Medline].

  13. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008 Oct. 17(4):787-801, viii-ix. [Medline]. [Full Text].

  14. Miller MT, Ventura L, Strömland K. Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol. 2009 Aug. 85(8):667-76. [Medline].

  15. Tedrus GM, Fonseca LC, Melo EM, Ximenes VL. Educational problems related to quantitative EEG changes in benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav. 2009 Aug. 15(4):486-90. [Medline].

  16. Watemberg N, Leitner Y, Fattal-Valevski A, Kramer U. Epileptic negative myoclonus as the presenting seizure type in rolandic epilepsy. Pediatr Neurol. 2009 Jul. 41(1):59-64. [Medline].

  17. Enstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs. 2009 May. 10(5):463-73. [Medline].

  18. Critchfield JW, van Hemert S, Ash M, Mulder L, Ashwood P. The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract. 2011. 2011:161358. [Medline]. [Full Text].

  19. Finegold SM, Downes J, Summanen PH. Microbiology of regressive autism. Anaerobe. 2012 Apr. 18(2):260-2. [Medline].

  20. Jyonouchi H, Geng L, Ruby A, et al. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. 2005 May. 146(5):605-10. [Medline].

  21. Stigler KA, Posey DJ, McDougle CJ. Ramelteon for insomnia in two youths with autistic disorder. J Child Adolesc Psychopharmacol. 2006 Oct. 16(5):631-6. [Medline].

  22. Malhotra S, Subodh BN, Parakh P, Lahariya S. Brief report: childhood disintegrative disorder as a likely manifestation of vitamin B12 deficiency. J Autism Dev Disord. 2013 Sep. 43(9):2207-10. [Medline].

  23. Rosman NP, Bergia BM. Childhood disintegrative disorder: distinction from autistic disorder and predictors of outcome. J Child Neurol. 2013 Dec. 28(12):1587-98. [Medline].

  24. Creten C, van der Zwaan S, Blankespoor RJ, Maatkamp A, Klinkenberg S, van Kranen-Mastenbroek VH, et al. [Anti-NMDA-receptor encephalitis: a new axis-III disorder in the differential diagnosis of childhood disintegrative disorder, early onset schizophrenia and late onset autism]. Tijdschr Psychiatr. 2012. 54(5):475-9. [Medline].

  25. American Psychiatric Association. Childhood Disintegrative Disorder 299.10. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994. 73-5.

  26. Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. 2008 Oct. 17(4):739-52, vii-viii. [Medline].

  27. Agarwal V, Sitholey P, Mohan I. Childhood Disintegrative Disorder, an atypical presentation: a case report. J Autism Dev Disord. 2005 Dec. 35(6):873-4. [Medline].

  28. Mordekar SR, Prendergast M, Chattopadhyay AK, Baxter PS. Corticosteroid treatment of behaviour, language and motor regression in childhood disintegrative disorder. Eur J Paediatr Neurol. 2008 Jul 13. [Medline].

  29. Russo M, Perry R, Kolodny E, Gillberg C. Heller syndrome in a pre-school boy. Proposed medical evaluation and hypothesized pathogenesis. Eur Child Adolesc Psychiatry. 1996 Sep. 5(3):172-7. [Medline].

  30. Akshoomoff N, Farid N, Courchesne E, Haas R. Abnormalities on the neurological examination and EEG in young children with pervasive developmental disorders. J Autism Dev Disord. 2007 May. 37(5):887-93. [Medline].

  31. Kurita H, Koyama T, Osada H. Comparison of childhood disintegrative disorder and disintegrative psychosis not diagnosed as childhood disintegrative disorder. Psychiatry Clin Neurosci. 2005 Apr. 59(2):200-5. [Medline].

  32. A Message From APA President Dilip Jeste, M.D., on DSM-5. Available at Accessed: December 1, 2012.

  33. Young EC, Diehl JJ, Morris D, et al. The use of two language tests to identify pragmatic language problems in children with autism spectrum disorders. Lang Speech Hear Serv Sch. 2005 Jan. 36(1):62-72. [Medline].

  34. Gibson RC, Walcott G. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2008 Oct 8. CD006570. [Medline].

  35. Cohen IL, Schmidt-Lackner S, Romanczyk R, Sudhalter V. The PDD Behavior Inventory: a rating scale for assessing response to intervention in children with pervasive developmental disorder. J Autism Dev Disord. 2003 Feb. 33(1):31-45. [Medline].

  36. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008. 69 Suppl 4:9-14. [Medline].

  37. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol. 2009 Jun. 19(3):265-74. [Medline].

  38. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009 Jun. 66(6):583-90. [Medline].

  39. Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008 Feb. 4(1):203-7. [Medline]. [Full Text].

  40. Posey DJ, Aman MG, McCracken JT, Scahill L, Tierney E, Arnold LE, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007 Feb 15. 61(4):538-44. [Medline].

  41. Carlson T, Reynolds CA, Caplan R. Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. J Am Acad Child Adolesc Psychiatry. 2007 Mar. 46(3):356-61. [Medline].

  42. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004 Nov. 19(6):351-3. [Medline].

  43. Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol. 2005 Jul. 19(4):422-5. [Medline].

  44. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. 2005 Sep. 112(3):238-40; discussion 240. [Medline].

  45. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006 Jul. 114(1):1-7. [Medline].

  46. Soares-Fernandes JP, Machado A, Ribeiro M, et al. Hippocampal involvement in valproate-induced acute hyperammonemic encephalopathy. Arch Neurol. 2006 Aug. 63(8):1202-3. [Medline].

  47. Stewart JT. Treatment of valproate-induced hyperammonemia. J Am Geriatr Soc. 2005 Jun. 53(6):1080. [Medline].

  48. [Guideline] Kagan-Kushnir T, Roberts SW, Snead OC 3rd. Screening electroencephalograms in autism spectrum disorders: evidence-based guideline. J Child Neurol. 2005 Mar. 20(3):197-206. [Medline].

  49. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007 May. 22(5):574-9. [Medline].

  50. Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry. 2008. 16(2):97-112. [Medline].

  51. Sonnier L, Barzman D. Pharmacologic management of acutely agitated pediatric patients. Paediatr Drugs. 2011 Feb 1. 13(1):1-10. [Medline].

  52. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2008 Oct. 17(4):803-20, ix. [Medline]. [Full Text].

  53. Duncan B, McDonough-Means S, Worden K, Schnyer R, Andrews J, Meaney FJ. Effectiveness of osteopathy in the cranial field and myofascial release versus acupuncture as complementary treatment for children with spastic cerebral palsy: a pilot study. J Am Osteopath Assoc. 2008 Oct. 108(10):559-70. [Medline].

  54. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev. 2005 Oct 19. CD003497. [Medline].

  55. Murch S. Diet, immunity, and autistic spectrum disorders. J Pediatr. 2005 May. 146(5):582-4. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.